Nanomedicine: current status and future prospects

被引:1365
作者
Moghimi, SM [1 ]
Hunter, AC
Murray, JC
机构
[1] Univ Brighton, Sch Pharm, Mol Targeting & Polymer Toxicol Grp, Brighton BN2 4GJ, E Sussex, England
[2] Univ Hosp, Wolfson Digest Dis Ctr, Canc Res UK, Tumour Cytokine Biol Grp, Nottingham, England
关键词
nanotechnology; nanosized drug delivery systems; nanoparticles; medical imaging; gene therapy; nanofibers; macrophage; endothelium; intracellular delivery; extravasation; toxicity;
D O I
10.1096/fj.04-2747rev
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Applications of nanotechnology for treatment, diagnosis, monitoring, and control of biological systems has recently been referred to as "nanomedicine" by the National Institutes of Health. Research into the rational delivery and targeting of pharmaceutical, therapeutic, and diagnostic agents is at the forefront of projects in nanomedicine. These involve the identification of precise targets (cells and receptors) related to specific clinical conditions and choice of the appropriate nanocarriers to achieve the required responses while minimizing the side effects. Mononuclear phagocytes, dendritic cells, endothelial cells, and cancers (tumor cells, as well as tumor neovasculature) are key targets. Today, nanotechnology and nanoscience approaches to particle design and formulation are beginning to expand the market for many drugs and are forming the basis for a highly profitable niche within the industry, but some predicted benefits are hyped. This article will highlight rational approaches in design and surface engineering of nanoscale vehicles and entities for site-specific drug delivery and medical imaging after parenteral administration. Potential pitfalls or side effects associated with nanoparticles are also discussed.
引用
收藏
页码:311 / 330
页数:20
相关论文
共 163 条
[31]   Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration [J].
Curnis, F ;
Sacchi, A ;
Corti, A .
JOURNAL OF CLINICAL INVESTIGATION, 2002, 110 (04) :475-482
[32]   Diffusion dynamics of glycine receptors revealed by single-quantum dot tracking [J].
Dahan, M ;
Lévi, S ;
Luccardini, C ;
Rostaing, P ;
Riveau, B ;
Triller, A .
SCIENCE, 2003, 302 (5644) :442-445
[33]   Systemic depletion of macrophages by liposomal bisphosphonates reduces neointimal formation following balloon-injury in the rat carotid artery [J].
Danenberg, HD ;
Fishbein, I ;
Epstein, H ;
Waltenberger, J ;
Moerman, E ;
Mönkkönen, J ;
Gao, XC ;
Gathi, I ;
Reichi, R ;
Golomb, G .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2003, 42 (05) :671-679
[34]   MR imaging of murine arthritis using ultrasmall superparamagnetic iron oxide particles [J].
Dardzinski, BJ ;
Schmithorst, VJ ;
Holland, SK ;
Boivin, GP ;
Imagawa, T ;
Watanabe, S ;
Lewis, JM ;
Hirsch, R .
MAGNETIC RESONANCE IMAGING, 2001, 19 (09) :1209-1216
[35]   Secreted phospholipase A2 as a new enzymatic trigger mechanism for localised liposomal drug release and absorption in diseased tissue [J].
Davidsen, J ;
Jorgensen, K ;
Andresen, TL ;
Mouritsen, OG .
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 2003, 1609 (01) :95-101
[36]   Synergistic permeability enhancing effect of lysophospholipids and fatty acids on lipid membranes [J].
Davidsen, J ;
Mouritsen, OG ;
Jorgensen, K .
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 2002, 1564 (01) :256-262
[37]  
Derfus AM, 2004, NANO LETT, V4, P11, DOI 10.1021/nl0347334
[38]   Lipid-protamine-DNA-mediated antigen delivery to antigen-presenting cells results in enhanced anti-tumor immune responses [J].
Dileo, J ;
Banerjee, R ;
Whitmore, M ;
Nayak, JV ;
Falo, LD ;
Huang, L .
MOLECULAR THERAPY, 2003, 7 (05) :640-648
[39]  
Dousset V, 1999, AM J NEURORADIOL, V20, P223
[40]  
Drummond DC, 1999, PHARMACOL REV, V51, P691